Novo Nordisk Shares Face Critical Test Amid Institutional Exodus
Published on 11/18/2025 at 20:31 | Redaktion boerse-global.de
Danish pharmaceutical leader Novo Nordisk is confronting a severe market downturn as major investors rapidly divest their holdings. The company’s stock has plummeted 58% from its peak levels and now approaches a crucial support threshold that could determine its near-term trajectory. This selling pressure follows management’s decision to significantly scale back annual performance expectations.
The core issue driving the selloff stems from disappointing operational developments. Novo Nordisk has substantially lowered its full-year 2025 guidance, now projecting revenue growth of just 8-11% at constant exchange rates, markedly below previous expectations.
Market analysts point to slowing momentum for the company’s flagship medications Wegovy and Ozempic as the primary concern. These former Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
